Korea United Pharm Inc. (033270) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Korea United Pharm Inc. (033270:KRX), powered by AI.

Current Price
₩18,650
P/E Ratio
7.7
Market Cap
296.7B
Sector
Healthcare
What is the Korea United Pharm Inc. stock price forecast?

Korea United Pharm Inc. is currently trading at ₩18,650. View real-time AI analysis on Alpha Lenz.

What is Korea United Pharm Inc. insider trading activity?

View the latest insider trading data for Korea United Pharm Inc. on Alpha Lenz.

What is Korea United Pharm Inc.'s P/E ratio?

Korea United Pharm Inc.'s P/E ratio is 7.7.

Korea United Pharm Inc.

KRX · 033270
₩18,650+150(+0.81%)Market closedKRX regular session 09:00–15:30 KST
Ask about Korea United Pharm Inc.'s future dividend policy...
Alpha Chat Insight

Korea United Pharm Inc. trades at a P/E of 7.7 (undervalued) with solid ROE of 8.9%.

Ask for details

Company Overview

Korea United Pharm Inc. is a pharmaceutical company that develops, manufactures, and distributes a wide range of medicinal products. Its primary function is to enhance healthcare treatment options through the provision of high-quality pharmaceuticals, spanning categories such as prescription drugs, over-the-counter medications, and health supplements. The company is known for its advanced research and development capabilities, fostering the creation of innovative drugs aimed at treating various health conditions. With a focus on therapeutic areas like cardiovascular, gastrointestinal, and antibiotic therapies, Korea United Pharm Inc. significantly contributes to public health improvements. In the financial market, it represents a key player in the healthcare sector, responding to both domestic and international demands for effective and affordable medication. Headquartered in South Korea, the company leverages its strong production facilities and comprehensive distribution networks to ensure the sustained delivery of healthcare solutions. By maintaining robust collaboration within the global pharmaceutical community, Korea United Pharm Inc. bolsters its strategic position, influencing both market trends and regulatory practices within the sector.

CEO강덕영
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
0

Company Statistics

FY 2025

Profile

₩296,735,953,750Market Cap
₩288,764,867,640Revenue
15.91MShares Out
0Employees

Margins

55.61%Gross
23.28%EBITDA
17.35%Operating
17.25%Pre-Tax
13.27%Net

Valuation

7.75P/E
0.65P/B
1.03EV/Sales
4.02EV/EBITDA
11.42P/FCF

Growth (CAGR)

3.23%Rev 3Yr
5.98%Rev 5Yr
1.30%Op Inc 3Yr
4.54%Op Inc 5Yr
-5.42%Net Inc 3Yr
7.56%Net Inc 5Yr

Returns

7.71%ROA
8.90%ROE
10.07%ROIC

Financial Health

₩40,293,976,330Cash & Cash Equivalents
₩24,568,418,240Net Debt
14.27%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Korea United Pharm Inc. (ticker: 033270) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $296.7B.

The current price is ₩18,650 with a P/E ratio of 7.75x and P/B of 0.65x.

ROE is 8.90% and operating margin is 17.35%. Annual revenue is $288.8B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Korea United Pharm Inc. (033270) Stock Forecast 2026 ₩18,650 — Price, Financials & Analyst Targets | Alpha Lenz